AnaptysBio, Inc. (NASDAQ:ANAB) CFO Sells $487,700.20 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. The sale was disclosed in a document filed with the SEC, which is available at this link.

AnaptysBio Price Performance

NASDAQ ANAB opened at $36.57 on Thursday. The stock’s 50 day simple moving average is $35.42 and its 200 day simple moving average is $27.69. AnaptysBio, Inc. has a one year low of $13.36 and a one year high of $41.31. The firm has a market cap of $999.06 million, a PE ratio of -5.96 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. As a group, equities analysts expect that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research report on Wednesday, August 14th. Finally, Truist Financial increased their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.30.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently modified their holdings of the stock. Algert Global LLC increased its holdings in shares of AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 1,078 shares in the last quarter. Frazier Life Sciences Management L.P. raised its holdings in AnaptysBio by 140.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after purchasing an additional 1,265,891 shares during the last quarter. Susquehanna Fundamental Investments LLC lifted its position in AnaptysBio by 32.9% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 72,060 shares of the biotechnology company’s stock valued at $1,806,000 after purchasing an additional 17,855 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of AnaptysBio by 49.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company’s stock valued at $634,000 after purchasing an additional 8,418 shares during the last quarter. Finally, Alpha DNA Investment Management LLC acquired a new stake in shares of AnaptysBio during the 2nd quarter worth approximately $399,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.